[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"all-childhood\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:all-childhood":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,41,67,87,111],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100519999","healthy-weight-intervention-families-during-all-treatment-nourish-all-100519999",false,"NCT06050850","Healthy Weight Intervention Families During ALL Treatment: NOURISH-ALL","A Healthy Weight Intervention for Family Stress During the Early Phases of ALL Treatment: NOURISH-ALL","NOURISH-ALL","Inclusion Criteria:\n\n* Children ages 2-12 years old and their primary caregiver ages 18-90\n* Child diagnosed with acute lymphoblastic leukemia (ALL)\n* Child completed induction phase of therapy and not yet in maintenance phase of therapy\n* Primary caregiver and child English language proficient\n* Primary caregiver able to provide permission for child to participate in research\n* Primary caregiver identifies as being involved with child's oncology care\n* Primary caregiver lives with child at least 50% of the time\n* Primary oncology provider confirms child is eligible to participate\n\nExclusion Criteria:\n\n* Primary oncology provider identifies safety concerns regarding the child's participation in the study.","ALL","2 Years","12 Years",{"count":21,"type":22},46,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to conduct a single arm pilot of the NOURISH-ALL (Nourishing Our Understanding of Role modeling to Improve Support and Health in Acute Lymphoblastic Leukemia) intervention focused on three components of participant engagement. This is a single arm intervention study that involves participation in a 6-session family intervention and three time points of multimethod data collection. The primary outcome is participant engagement, measured as recruitment, retention, and intended dose received.\n\nThis study will be conducted over 5 years in three phases:\n\n* Aim 1a: Adapting the NOURISH-ALL Intervention for Families of Youth with ALL (Year 1)\n* Aim 1b: Iteratively Refining the NOURISH-ALL Intervention (Year 2)\n* Aim 2: Pilot Single-Arm Trial of NOURISH-ALL Focused on Participant Engagement (Years 3-5)",[26,27],"ALL, Childhood","Behavior, Health","RECRUITING","2026-06-30",{"date":31,"type":32},"2026-07-02","ACTUAL",{"date":34,"type":32},"2023-10-17",{"date":36,"type":22},"2028-09-01",{"name":38,"class":39},"University of Kansas Medical Center","OTHER",2,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":17,"minAge":48,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":40},"100329599","phase-1-ruxolitinib-and-chemotherapy-in-adolescents-and-young-adults-with-ph-like-acute-lymphoblastic-leukemia-100329599","NCT03571321","Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia","Phase I Trial of Ruxolitinib in Combination With a Pediatric Based-regimen for Adolescents and Young Adults (AYAs) With Ph-like Acute Lymphoblastic Leukemia (ALL)","Inclusion Criteria:\n\n* Newly diagnosed de novo B-precursor acute lymphoblastic leukemia (ALL) as determined by World Health Organization (WHO) criteria. Patients must have unequivocal diagnosis of precursor B ALL. This includes an institutional immunophenotyping report that is to assign B-lineage or T-lineage.\n* \"Ph-like\" signature, as determined by low density micro-array (LDA) card\n* Jak-targetable genetic signature as defined by any of the following:\n\n  * Cytokine receptor-like factor 2 (CRLF2) rearranged (JAK2 mutant or wild-type)\n  * JAK2 or erythropoietin receptor (EPOR) fusions.\n  * Other JAK pathway alterations at the discretion of the principle investigator including, but not limited to:\n* SH2B adaptor protein 3 (SH2B3) deletions\n* Interleukin-7 receptor subunit alpha (IL7RA) mutations\n* Prior therapy\n\n  * Prior to starting ruxolitinib, patients must have completed a 4-drug induction regimen with intrathecal chemotherapy (modified aBFM regimen or equivalent) as per the institutional standard of care. Recommended induction treatment is outlined in Section 5.1.2.\n  * No additional prior therapy for acute leukemia except emergency therapy (corticosteroids or hydroxyurea) for blast cell crisis, superior vena cava syndrome, or renal failure due to leukemic infiltration of the kidneys. When indicated, leukapheresis or exchange transfusion is recommended to reduce the white blood cell count (WBC).\n  * Screening may occur at any point prior to or during induction therapy\n* Age ≥ 18 years and \\\u003C 40 years. Because this is specifically a study of the adolescent and young adult population and no adverse event data are currently available on the use of this pediatric-based chemotherapy regimen in patients ≥ 40 years of age, older adults are excluded from this study, but may be eligible for future trials.\n* Eastern Cooperative Oncology Group (ECOG) performance status ≤2 (Karnofsky ≥ 60%)\n* Platelet count \\> 25,000\u002FuL.\n* Patients must have normal organ function as defined below:\n\n  * total bilirubin ≤ 2 mg\u002FdL\n  * aspartate aminotransferase (AST) \u002F alanine aminotransferase (ALT) ≤ 2.5 × institutional upper limit of normal\n  * creatinine within normal institutional limits OR creatinine clearance ≥ 60 mL\u002Fmin\u002F1.73 m2 for patients with creatinine levels above institutional normal.\n* Because the therapeutic agents used in this study are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation.\n* Ability to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n* Patients who are receiving any other investigational agent.\n* Patients with a \"currently active\" second malignancy other than non-melanoma skin cancers. Patients are not considered to have a \"currently active\" malignancy if they have completed therapy and are free of disease for ≥ 3 years.\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to ruxolitinib or other agents used in study.\n* Use of any potent cytochrome P450 (CYP) 3A4 inhibitor or inducer within 5 half-lives before the first dose of the study drug. Potent inhibitors of CYP3A4 include systemic ketoconazole, posaconazole, voriconazole, clarithromycin, itraconazole, nefazodone, and telithromycin. At the fluconazole dose of 200mg daily used this regimen, there is minimal inhibition of CYP3A4 \\[36\\] and therefore fluconazole is not prohibited on this trial and no dose modifications should be made in the presence of fluconazole.\n\nBecause the lists of these agents are constantly changing, it is important to regularly consult a frequently-updated list such as http:\u002F\u002Fmedicine.iupui.edu\u002Fclinpharm\u002Fddis\u002Ftable.aspx; medical reference texts such as the Physicians' Desk Reference may also provide this information. As part of the enrollment\u002Finformed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product.\n\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.\n* Pregnant women are excluded from this study because ruxolitinib is a class C agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with ruxolitinib breastfeeding should be discontinued if the mother is treated with ruxolitinib. These potential risks may also apply to other agents used in this study.\n* Down Syndrome due to the likelihood of excessive toxicity resulting. These patients should be treated in consultation with a pediatric oncologist.\n* Burkitt type leukemia\n* Ph+ ALL at time of diagnosis","18 Years","39 Years",{"count":51,"type":22},15,"INTERVENTIONAL",[54],"PHASE1","This study will test if adding ruxolitinib to standard multi-drug chemotherapy regimen will be safe and tolerated in adolescents and young adults with newly diagnosed Ph-like acute lymphoblastic leukemia (ALL).",[57,26,17],"Acute Lymphoblastic Leukemia","2026-06-24",{"date":60,"type":32},"2026-06-29",{"date":62,"type":32},"2019-05-28",{"date":64,"type":22},"2027-09-05",{"name":66,"class":39},"University of Chicago",{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":71,"acronym":4,"eligibilityCriteria":72,"healthyVolunteers":11,"sex":17,"minAge":48,"maxAge":49,"enrollmentInfo":73,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":75,"conditions":76,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":86},"100497902","childhood-cancer-survivors-affective-response-to-exercise-100497902","NCT05763290","Childhood Cancer Survivors' Affective Response to Exercise","Inclusion Criteria:\n\n* Participants enrolled in St. Jude Lifetime Cohort (SJLIFE) aged 18-39 years at completion of on campus visit\n* Primary diagnosis of acute lymphoblastic leukemia (ALL)\n* No cranial radiation therapy (CRT) as part of treatment for ALL\n* Identify as physically inactive (do not meet Centers for Disease Control and Prevention (CDC) guidelines of 150 minutes of moderate physical activity per week or 75 minutes of vigorous physical activity per week)\n* Women who are not currently pregnant\n\nExclusion Criteria:\n\n* Individuals who cannot speak, read, and\u002For understand English.\n* Individuals with an estimated IQ of \\\u003C70 and\u002For per PI discretion\n* Individuals with any contraindication to stress testing (i.e. cardiovascular complications)\n* Women who are currently pregnant",{"count":74,"type":22},125,"The primary objective of this study is to assess the feasibility of administering the Personalized Single-Category Implicit Association Test (PSC-IAT) to young adult survivors of childhood cancer.\n\nParticipants will perform a total of three trials of a cognitive task before and after their scheduled SJLIFE cardiovascular stress testing. Participants will then be asked to participate in a qualitative interview about the cognitive task tool and body sensations and emotions experienced during exercise.",[26,57],"2026-04-21",{"date":79,"type":32},"2026-04-23",{"date":81,"type":32},"2023-03-22",{"date":83,"type":22},"2030-02",{"name":85,"class":39},"St. Jude Children's Research Hospital",1,{"id":88,"slug":89,"hasResults":11,"nctId":90,"briefTitle":91,"officialTitle":91,"acronym":4,"eligibilityCriteria":92,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":93,"enrollmentInfo":94,"targetDuration":4,"studyType":52,"phases":96,"briefSummary":97,"conditions":98,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":86},"100541177","phase-1-car-t-cell-therapy-directed-to-cd70-for-pediatric-patients-with-hematological-malignancies-100541177","NCT06326463","CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies","Inclusion Criteria\n\nAge ≤21 years old\n\nRelapsed\u002Frefractory CD70+ hematological malignancy\n\nRelapsed disease: Patients developing recurrent disease after a prior complete remission (CR)\n\nRefractory disease: Patients with persistent disease despite 3 cycles of induction chemotherapy.\n\n* Relapsed\u002Frefractory CD70+ AML or MDS:\n\n  * Relapsed disease that is CD70 positive\n  * Refractory disease that is persistent despite 3 cycles of chemotherapy\n* Relapsed\u002Frefractory CD70+ B-cell ALL:\n\n  * Relapsed disease that is CD70 positive and CD19 negative\u002Fdim or patients otherwise ineligible for CD19-directed therapies including:\n  * Patients in 2nd or greater relapse\n  * Patients with relapse after allogeneic HSCT\n* Relapsed\u002Frefractory CD70+ T-cell ALL:\n\n  * Relapsed \u002Frefractory disease that is CD70 positive\n* Mixed Phenotype Acute Leukemia (MPAL):\n\n  * Relapsed\u002Frefractory that is CD70 positive\n* Relapsed\u002Frefractory CD70+ lymphoma:\n\n  * Relapsed disease that is CD70 positive and CD19 negative\u002Fdim or patients otherwise ineligible for CD19-directed therapies including:\n  * Patients in 2nd or greater relapse\n  * Patients with relapse after allogeneic HSCT\n\nEstimated life expectancy of \\>12 weeks\n\nKarnofsky or Lansky (age- dependent) performance score ≥50\n\nPatients with a history of prior allogeneic HCT must be clinically recovered from prior HCT therapy, have no evidence of active GVHD and have not received a donor lymphocyte infusion (DLI) within the 28 days prior to apheresis\n\nPatient must have an identified HCT donor\n\nFor females of childbearing age:\n\ni. Not lactating with intent to breastfeed\n\nii. Not pregnant with negative serum or urine pregnancy test within 7 days prior to enrollment\n\nExclusion Criteria\n\n* Known primary immunodeficiency\n* Known history of HIV positivity\n* Severe intercurrent bacterial, viral or fungal infection\n* History of hypersensitivity to cornstarch or hydroxyethyl starch\n* Patients with acute promyelocytic leukemia (APL)\n* Known contraindication to protocol defined lymphodepleting\n* chemotherapy regimen of Fludarabine\u002Fcyclophosphamide","21 Years",{"count":95,"type":22},18,[54],"The study participant has one of the following blood cancers: acute myelogenous leukemia (AML)\u002Fmyelodysplastic syndrome (MDS), acute lymphoblastic leukemia (B-ALL, T-ALL) or Lymphoma. Your cancer has been difficult to treat (refractory) or has come back after treatment (relapse).\n\nPrimary Objective\n\nTo determine the safety and maximum tolerated dose of intravenous infusions of escalating doses of CD70-CAR T cells in patients (≤21 years) with recurrent\u002Frefractory CD70+ hematological malignancies after lymphodepleting chemotherapy.\n\nSecondary Objectives\n\nTo evaluate the antileukemic activity of CD70-CAR T cells. We will determine the anti- leukemic activity of the CD70-CAR T cells in the bone marrow and in the treatment of extramedullary disease.",[99,26,100,101,102],"Hematologic Malignancy","AML, Childhood","Lymphoma","MDS","2026-01-22",{"date":105,"type":32},"2026-01-23",{"date":107,"type":32},"2024-10-16",{"date":109,"type":22},"2031-07-01",{"name":85,"class":39},{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":117,"eligibilityCriteria":118,"healthyVolunteers":11,"sex":17,"minAge":119,"maxAge":48,"enrollmentInfo":120,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":122,"conditions":123,"keywords":131,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":40},"100478607","pharmacogenomic-association-study-in-indian-children-with-acute-lymphoblastic-leukemia-100478607","NCT05512169","Pharmacogenomic Association Study in Indian Children With Acute Lymphoblastic Leukemia","Molecular and Pharmacogenetic Marker Evaluation in Relation to the Toxicity and Clinical Response of Acute Lymphoblastic Leukemia Treatment in Indian Children (MPGx-INDALL)","MPGx-INDALL","Inclusion Criteria:\n\n* Age \\> 1 year old and ≤18 years old at enrolment\n* Previously untreated\n* ALL diagnosis confirmed by morphology and flow-cytometry\n* Indian origins\n* Fulfilling IciCle treatment protocol inclusion criteria and receiving treatment as per the protocol\n* Written Informed consent to participate in the study has to be signed by the participant\u002Fparent\u002Fguardian\n\nExclusion Criteria:\n\n* Previously tretaed patients\n* Patients with Down's syndrome\n* Patients with mature B-ALL","1 Year",{"count":121,"type":22},556,"A five-year prospective observational cohort study. The study is focused on observing the relation between static germline variants and therapeutic response in Indian children with acute lymphoblastic leukemia (ALL). The project is an International multicenter setup. This collaborative research project between Switzerland and India includes one main center in Geneva that has conceptualized, designed, received grants for the study and two investigating centers in India (Puducherry and New-Delhi) involved in study design, patient care and recruitment for this specific study. All the participants for the study will be recruited form these two centers in India, and no patient recruitment is planned at main center i.e. Geneva.\n\nThe study will be conducted in two phases. The first aims to investigate genetic predisposition (static germline variants) to early chemotherapy treatment related toxicities (TRTs). The second aims to investigate somatic genetic markers associated with the efficacy of steroid treatment among patients undergoing the standardized IciCLe-ALL-14 treatment protocol. A total of 500 children with ALL will be recruited to investigate primary objective of the study i.e. TRT, and a subset of 250 patients will be included to investigate another research question i.e. response to steroid therapy.",[26,124,125,126,127,128,129,130],"Pediatric Cancer","Toxicity, Drug","Adverse Drug Event","Relapse Leukemia","Drug Toxicity","Drug Effect","Drug Interaction",[132,133,134,135,136,137,138,139,140,141,142,143,144,145],"Pharmacogenetics","Pharmacogenomics","Genetic polymorphism","Sequencing","Genotyping","Indian","Pediatrics","SNP","gene variant","germline genetic variant","somatic variant","biomarker","steroid response","genetic predisposition","2026-01-13",{"date":148,"type":32},"2026-01-15",{"date":150,"type":32},"2022-12-01",{"date":152,"type":22},"2027-03-30",{"name":154,"class":39},"University of Geneva, Switzerland"]